Latest Announcements
Ladenburg Thalmann Acts as Sole Book-Running Manager for Kiora Pharmaceuticals, Inc. in its $6.0 Million Underwritten Public Offering
Transaction Information Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the...
Ladenburg Thalmann Acts as Exclusive Financial Advisor to Athenex, Inc. (Nasdaq: ATNX) in its $85 Million Royalty Monetization
Transaction Information Athenex, Inc. (NASDAQ: ATNX, "Athenex", or "the Company) is a global biopharmaceutical company focused on novel therapies for cancer and related conditions. At the beginning of 2022,...
Ladenburg Thalmann Acts as Exclusive Placement Agent for Vallon Pharmaceuticals, Inc. (VLON) in its $3.9 Million Registered Direct Offering
Transaction Information Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a...
Ladenburg Thalmann acted as Lead Bookrunner for Saratoga Investment Corp. on its $87.5 million offering of Unsecured Notes
Transaction Information New York, NY - Saratoga Investment Corp. (NYSE:SAR) (the "Company") announced that it has priced an underwritten public offering of $87.5 million in aggregate principal amount of 6.00%...
Ladenburg Thalmann Acts as Co-Lead Manager for SCYNEXIS, Inc. (SCYX) in its $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Transaction Information SCYNEXIS, Inc. (Nasdaq: SCYX) announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were...
Ladenburg Thalmann Acts as Sole Book-Running Manager for Ra Medical Systems, Inc. (RMED) in its $12.1 Million Follow-On Offering
Transaction Information Ra Medical Systems, Inc. (NYSE American: RMED) announced the closing of an underwritten public offering of units and pre-funded units for aggregate gross proceeds of approximately $12.1...
Ladenburg Thalmann Acts as Exclusive Placement Agent for NovaBay Pharmaceuticals (NBY) in its $15.0 Million Private Placement
Transaction Information NovaBay Pharmaceuticals, Inc. (NBY) announced it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a private placement of 15,000...
Ladenburg Thalmann Acts as Lead Manager for Evaxion Biotech in its $27.6 Million Follow-On Offering
Transaction Information Evaxion Biotech A/S (NASDAQ: EVAX), announced the closing of its follow-on public offering of 3,942,856 American Depositary Shares ("ADSs"), at a public offering price of $7.00 per ADS,...
Ladenburg Thalmann Acts as Sole Book-Running Manager for Helius Medical Technologies, Inc. (HSDT) in its $11.1 Million Follow-On Offering
Transaction Information Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) announced underwritten public offering of 1,385,031 shares of its Class A common stock at a price to the public of $8.00 per...
Ladenburg Thalmann Acts as Sole Book-Running Manager for Nuwellis, Inc. (NUWE) in its $10.0 Million Follow-On Offering
Transaction Information Nuwellis, Inc. (NASDAQ: NUWE), announced the closing of its previously announced underwritten public offering of 4,005,588 shares of its common stock at a price to the public of $2.50 per...
Ladenburg Thalmann Acts as Exclusive Placement Agent for Hancock Jaffe Laboratories (HJLI) in its $20 Million Registered Direct Offering Priced At-the-Market
Transaction Information Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) announced it has entered into a definitive agreement with a fund managed by Perceptive Advisors to purchase $20 million of its common stock...
Ladenburg Thalmann Acts as Co-Manager for Onconova Therapeutics, Inc. (ONTX) in its $21.0 Million Follow-On Offering
Transaction Information Onconova Therapeutics, Inc. (NASDAQ: ONTX), announced the closing of its previously-announced underwritten public offering of 5,000,000 shares of common stock at a public offering price of...